Founder of Curidium Launches Elixior, an Advisory Company Focused on the Development and Growth of Innovative Personalized Medicine Businesses

LONDON - Elixior Limited, the advisory company focused on the development and growth of innovative personalized medicine businesses, announced today its launch by the founder and former CEO of Curidium, Dr Anne Bruinvels.

Elixior’s business activities are aimed at:

- Supporting the development and growth of personalized medicine businesses through the creation of partnerships and / or the sourcing of investments - Helping personalized medicine companies with the structuring of their corporate and commercial strategies - Conducting due diligence on personalized medicine ventures - Building a world-wide, personalized medicine knowledge-base to support cooperation between personalized medicine businesses and the growth of the sector.

Dr Anne Bruinvels, founder and CEO of Elixior, commented: “The field of personalized medicine is moving forward rapidly and it is Elixior’s aim to help the development and commercialization of new innovations in this exciting area. Personalized medicine has the potential to treat patients more effectively and to make healthcare much more cost-effective over time. I look forward to working with small and big companies alike planning to move into or expand in this field.”

Previously, Dr Anne Bruinvels founded Curidium, a personalized medicine company focused on improving the diagnosis and treatment of central nervous system disorders. She was Curidium’s CEO for more than six years, during which she took the company public on the AIM of the London Stock Exchange.

About Personalized Medicine

The term personalized medicine means the use of molecular analysis methods to better manage a patient’s disease or disease predisposition. These methods include testing for variations in genes, gene expression, proteins, and metabolites. Test results are correlated with clinical factors-such as drug response, disease state, and treatment prognosis-and help physicians individualize treatment for each patient.

Further information on Elixior can be found at the Company’s website: www.elixior.com. or further information, please contact:

Anne Bruinvels, CEO Phone: +44(0)77-67-807-865 E-mail: anne.bruinvels@elixior.com

Source: Elixior Limited

Anne Bruinvels, CEO, Phone: +44(0)77-67-807-865, E-mail: anne.bruinvels at elixior.com